Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

키워드

참고문헌 (78)

1. Ludwig J, "Nonalcoholic steatohepatitis : Mayo Clinic experiences with a hitherto unnamed disease", Mayo Clin Proc, 55, pp.434~438 (1980)
2. Fleming KA, "Mallory bodies in alcoholic and non-alcoholic liver disease contain a common antigenic determinant", Gut, 22, pp.341~344 (1981)
3. Michael H. Le, "2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis", Clinical Gastroenterology and Hepatology, 20(12), pp.2809~2817.e28 (2022), Elsevier BV[DOI]
4. Grace En Hui Lim, "An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD", Clinical Gastroenterology and Hepatology, 21(3), pp.619~629.e7 (2023), Elsevier BV[DOI]
5. Li J, "Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 4, pp.389~398 (2019)
6. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American association for the study of liver diseases", Hepatology, 67, pp.328~357 (2018)
7. Muthiah MD, "A clinical overview of non-alcoholic fatty liver disease : a guide to diagnosis, the clinical features, and complications-what the non-specialist needs to know", Diabetes Obes Metab, 24(Suppl 2), pp.3~14 (2022)
8. Huang DQ, "Global epidemiology of NAFLD-related HCC : trends, predictions, risk factors and prevention", Nat Rev Gastroenterol Hepatol, 18, pp.223~238 (2021)
9. Huang DQ, "Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis : a prospective study", Aliment Pharmacol Ther, 55, pp.820~827 (2022)
10. Emhmed Ali S, "Sarcopenic obesity in non-alcoholic fatty liver disease-the union of two culprits", Life(Basel), 11, pp.119~ (2021)
11. Park J, "NASH", liver fibrosis prevalence and incidence of nonliver comorbidities among people with NAFLD and Incidence of NAFLD by metabolic comorbidities : lessons from South Korea, 2021, pp.39, 634~645
12. Ampofo AG, "Beyond 2020 : modelling obesity and diabetes prevalence", Diabetes Res Clin Pract, 167, pp.108362~ (2020)
13. Ward ZJ, "Projected U. S. state-level prevalence of adult obesity and severe obesity", N Engl J Med, 381, pp.2440~2450 (2019)
14. Jie Ning Yong, "Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review", Clinical Gastroenterology and Hepatology, 21(1), pp.45~54.e6 (2023), Elsevier BV[DOI]
15. Muthiah MD, "Current management of non-alcoholic steatohepatitis", Liver Int, 40(Suppl 1(Suppl 1)), pp.89~95 (2020)
16. Xiao J, "Is fatty liver associated with depression? A meta-analysis and systematic review on the prevalence, risk factors, and outcomes of depression and non-alcoholic fatty liver disease", Front Med(Lausanne), 8, pp.691696~ (2021)
17. Polanco-Briceno S, "Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists", BMC Res Notes, 9, pp.157~ (2016)
18. Li J, "Non-alcoholic fatty liver disease(NAFLD)in Asia-more efforts are needed", Liver Int, 40, pp.3144~ (2020)
19. Lazarus JV, "The global NAFLD policy review and preparedness index : are countries ready to address this silent public health challenge?", J Hepatol, 76, pp.771~780 (2022)
20. Loomba R, "Mechanisms and disease consequences of nonalcoholic fatty liver disease", Cell, 184, pp.2537~2564 (2021)
21. Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease : an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
22. Eslam M, "MAFLD : a consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014 (2020)
23. Eslam M, "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease", Hepatol Int, 14, pp.889~919 (2020)
24. Nguyen VH, "Differential clinical characteristics and mortality outcomes in persons with NAFLD and", or MAFLD, 2021, pp.19, 2172~2181
25. Zheng Q, "Systematic review with meta-analysis : prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B", Aliment Pharmacol Ther, 54, pp.1100~1109 (2021)
26. Fernandez-Fuertes M, "Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection", Sci Rep, 10, pp.6736~ (2020)
27. Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
28. Kim D, "Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States", J Hepatol, 75, pp.1284~1291 (2021)
29. Huang Q, "NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-results from NHANES III", Front Med(Lausanne), 8, pp.693507~ (2021)
30. Lee H, "Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk : a nationwide cohort study", Clin Gastroenterol Hepatol, 19, pp.2138~2147 (2021)
31. Liang Y, "Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease : a 4. 6-year cohort study in China", J Clin Endocrinol Metab, 107, pp.88~97 (2022)
32. Yoneda M, "Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view : a retrospective nationwide claims database study in Japan", J Gastroenterol, 56, pp.1022~1032 (2021)
33. Yun Bin Lee, "Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B", Clinical and Molecular Hepatology, 25(1), pp.52~64 (2019), 대한간학회
34. Li J, "High rate of progression to cirrhosis in chronic hepatitis B(CHB)patients with non-alcoholic fatty liver(FL)", Gastroenterology, 152, pp.S1081~S1082 (2017)
35. Zheng KI, "Clinical utility of the MAFLD definition", J Hepatol, 74, pp.989~991 (2021)
36. Wang MF, "Clinic-pathological features of metabolic associated fatty liver disease with hepatitis B virus infection", World J Gastroenterol, 27, pp.336~344 (2021)
37. Al-Omary A, "The importance and impact of recognizing metabolic dysfunctionassociated fatty liver disease in patients with chronic hepatitis C", J Dig Dis, 23, pp.33~43 (2022)
38. van Kleef LA, "Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B", JHEP Rep, 3, pp.100350~ (2021)
39. Lin YP, "Personalized medicine impact of MAFLD on HBV-related stage 0", A hepatocellular carcinoma after curative resection impact of MAFLD on HBV-related, 2021, pp.11, 684~
40. Choi HSJ, "Nonalcoholic steatohepatitis is associated with liverrelated outcomes and all-cause mortality in chronic hepatitis B", Hepatology, 71, pp.539~548 (2020)
41. Kim MN, "Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver", Aliment Pharmacol Ther, 55, pp.97~107 (2022)
42. Li J, "Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B", J Infect Dis, 224, pp.294~302 (2021)
43. Mak LY, "Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B", J Hepatol, 73, pp.800~806 (2020)
44. Chu CM, "Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection?", Int J Obes (Lond), 31, pp.871~875 (2007)
45. Chu CM, "Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without", Dig Dis Sci, 58, pp.275~281 (2013)
46. Oh JH, "Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy", Hepatol Int, 15, pp.892~900 (2021)
47. Mak LY, "Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection", Hepatol Int, 15, pp.901~911 (2021)
48. Wong SW, "Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B", J Viral Hepat, 27, pp.1297~1305 (2020)
49. Targher G, "The complex link between NAFLD and type 2 diabetes mellitus-mechanisms and treatments", Nat Rev Gastroenterol Hepatol, 18, pp.599~612 (2021)
50. Kushner RF, "Assessment and lifestyle management of patients with obesity : clinical recommendations from systematic reviews", JAMA, 312, pp.943~952 (2014)
51. Yilmaz Y, "A single-letter change in an acronym : signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD", Expert Rev Gastroenterol Hepatol, 15, pp.345~352 (2021)
52. Eslam M, "Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases", Lancet Gastroenterol Hepatol, 6, pp.743~753 (2021)
53. Jong Hwa Choi, "The effect of moderate alcohol drinking in nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 26(4), pp.662~669 (2020), 대한간학회[DOI]
54. GBD 2016 Alcohol Collaborators, "Alcohol use and burden for 195countries and territories, 1990-2016 : a systematic analysis for the Global Burden of Disease Study 2016", Lancet, 392, pp.1015~1035 (2018)
55. Crabb DW, "Diagnosis and treatment of alcohol-associated liver diseases : 2019 practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 71, pp.306~333 (2020)
56. Cherpitel CJ, "Recall bias across 7 days in self-reported alcohol consumption prior to injury among emergency department patients", Drug Alcohol Rev, 37, pp.382~388 (2018)
57. Quek J, "Metabolic associated fatty liver disease increases the risk of systemic complications and mortality. A meta-analysis and systematic review of 12 620 736 individuals", Endocr Pract, 28, pp.667~672 (2022)
58. Canbay A, "Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 52, pp.1185~1194 (2020)
59. Le MH, "Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011-2016", J Intern Med, 287, pp.711~722 (2020)
60. Shiha G, "Nomenclature and definition of metabolic-associated fatty liver disease : a consensus from the Middle East and North Africa", Lancet Gastroenterol Hepatol, 6, pp.57~64 (2021)
61. Nan Y, "The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease", J Hepatol, 75, pp.454~461 (2021)
62. Shaltout I, "Arabic Association for the Study of Diabetes and Metabolism(AASD)endorsing the MAFLD definition of fatty liver disease", J Hepatol, 76, pp.739~740 (2022)
63. Mendez-Sanchez N, "The Latin American Association for the Study of the Liver(ALEH)position statement on the redefinition of fatty liver disease", Lancet Gastroenterol Hepatol, 6, pp.65~72 (2021)
64. Méndez-Sánchez N, "Global multi-stakeholder endorsement of the MAFLD definition", Lancet Gastroenterol Hepatol, 7, pp.388~390 (2022)
65. Singh SP, "Non-alcoholic fatty liver disease: not time for an obituary just yet!", J Hepatol, 74, pp.972~974 (2021)
66. Younossi ZM, "From NAFLD to MAFLD: implications of a premature change in terminology", Hepatology, 73, pp.1194~1198 (2021)
67. Francque SM, "A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH", N Engl J Med, 385, pp.1547~1558 (2021)
68. Younossi ZM, "Obeticholic acid for the treatment of nonalcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
69. Loomba R, "Advances in non-invasive assessment of hepatic fibrosis", Gut, 69, pp.1343~1352 (2020)
70. Harrison SA, "A blood-based biomarker panel(NIS4)for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis : a prospective derivation and global validation study", Lancet Gastroenterol Hepatol, 5, pp.970~985 (2020)
71. Dela Cruz AC, "379 characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease", Gastroenterology, 146, pp.S909~ (2014)
72. Hagström H, "Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease : a long-term followup study", Hepatol Commun, 2, pp.48~57 (2017)
73. Zou B, "Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016", J Intern Med, 288, pp.139~151 (2020)
74. Ito T, "The epidemiology of NAFLD and lean NAFLD in Japan : a metaanalysis with individual and forecasting analysis, 1995-2040", Hepatol Int, 15, pp.366~379 (2021)
75. Younes R, "Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean : time for reappraisal of BMI-driven approach?", Gut, 71, pp.382~390 (2022)
76. Wong VW, "Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017-part 1 : definition, risk factors and assessment", J Gastroenterol Hepatol, 33, pp.70~85 (2018)
77. Chitturi S, "The Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017-part 2 : management and special groups", J Gastroenterol Hepatol, 33, pp.86~98 (2018)
78. European Association for the Study of the Liver (EASL), "EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease", Journal of Hepatology, 64(6), pp.1388~1402 (2016), Elsevier BV[DOI]

관련 논문AI추천